Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series

被引:167
作者
Fedele, Stefano [1 ]
Porter, Stephen R.
D'Aiuto, Francesco
Aljohani, Suad
Vescovi, Paolo [2 ]
Manfredi, Maddalena [2 ]
Arduino, Paolo G. [3 ]
Broccoletti, Roberto [3 ]
Musciotto, Anna [4 ]
Di Fede, Olga [4 ]
Lazarovici, Tony S. [5 ]
Campisi, Giuseppina [4 ]
Yarom, Naom [5 ,6 ]
机构
[1] UCL, Eastman Dent Inst, Oral Med Unit, Div Maxillofacial Diagnost Med & Surg Sci, London WC1X 8LD, England
[2] Univ Parma, Unit Oral Med Pathol Laser Assisted Surgery Parma, I-43100 Parma, Italy
[3] Univ Turin, Lingotto Dent Inst, Oral Med Sect, Dept Biomed Sci & Human Oncol, Turin, Italy
[4] Univ Palermo, Dept Stomatol Sci, Oral Med Sect, Palermo, Italy
[5] Chaim Sheba Med Ctr, Dept Oral & Maxillofacial Surg, IL-52621 Tel Hashomer, Israel
[6] Tel Aviv Univ, Sch Dent Med, Dept Oral Pathol & Oral Med, IL-69978 Tel Aviv, Israel
关键词
Avascular necrosis; Bisphosphonates; Jawbones; Jaws; Mandible; Maxilla; Osteochemonecrosis; Osteonecrosis; RISK-FACTORS; ORAL BISPHOSPHONATES; MULTIPLE-MYELOMA; BEAGLE DOGS; CANCER; HEAD;
D O I
10.1016/j.amjmed.2010.04.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw-a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. METHODS: Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. RESULTS: The most common clinical feature of nonexposed osteonecrosis was jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6). CONCLUSIONS: Clinicians should be highly vigilant to identify individuals with nonexposed osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 1060-1064
引用
收藏
页码:1060 / 1064
页数:5
相关论文
共 23 条
  • [1] Cancer Treatment Dosing Regimens of Zoledronic Acid Result in Near-Complete Suppression of Mandible Intracortical Bone Remodeling in Beagle Dogs
    Allen, Matthew R.
    Kubek, Daniel I.
    Burr, David B.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 98 - 105
  • [2] *AM DENT ASS COUNC, DENT MANAG PAT REC O
  • [3] Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies
    Assael, Leon A.
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 35 - 43
  • [4] Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
    Badros, Ashraf
    Terpos, Evangelos
    Katodritou, Eirini
    Goloubeva, Olga
    Kastritis, Efstathios
    Verrou, Evgenia
    Zervas, Kostas
    Baer, Maria R.
    Meiller, Timothy
    Dimopoulos, Meletios A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5904 - 5909
  • [5] Recent advances in Oral Oncology 2008; squamous cell carcinoma aetiopathogenesis and experimental studies
    Bagan, Jose V.
    Scully, Crispian
    [J]. ORAL ONCOLOGY, 2009, 45 (07) : E45 - E48
  • [6] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [7] Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
    Boonyapakorn, Thacharot
    Schirmer, Ingrid
    Reichart, Peter A.
    Sturm, Isrid
    Massenkeil, Gero
    [J]. ORAL ONCOLOGY, 2008, 44 (09) : 857 - 869
  • [8] Mandibular necrosis in beagle dogs treated with bisphosphonates
    Burr, D. B.
    Allen, M. R.
    [J]. ORTHODONTICS & CRANIOFACIAL RESEARCH, 2009, 12 (03) : 221 - 228
  • [9] Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
    Edwards, Beatrice J.
    Gounder, Mrinal
    Mckoy, June M.
    Boyd, Ian
    Farrugia, Mathew
    Migliorati, Cesar
    Marx, Robert
    Ruggiero, Salvatore
    Dimopoulos, Meletios
    Raisch, Dennis W.
    Singhal, Seema
    Carson, Ken
    Obadina, Eniola
    Trifilio, Steve
    West, Dennis
    Mehta, Jayesh
    Bennett, Charles L.
    [J]. LANCET ONCOLOGY, 2008, 9 (12) : 1166 - 1172
  • [10] Osteonecrosis Head of the Humeral Head
    Harreld, Kevin L.
    Marker, David R.
    Wiesler, Ethan R.
    Shafiq, Babar
    Mont, Michael A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, 2009, 17 (06) : 345 - 355